Ginkgo Bioworks reports 2022 revenue up 52% to $478M; guides 2023 total revenue at least $275M

Ginkgo Bioworks Holdings, Inc.

2022-FY EPS reported -$1.25 revenue$477,706,000

Full year 2022 total revenue $478M (+52% YoY); Foundry $144M (+27%), Biosecurity $334M (+66%).
Adjusted EBITDA loss widened to $(173)M in 2022 from $(106)M in 2021; operating loss $(2.2)B includes $1.9B stock comp.
2023 guidance: 100 new Cell Programs; total revenue at least $275M (Foundry ≥$175M, Biosecurity ≥$100M).
Cash and equivalents over $1.3B; filing extension for 10-K due to becoming large accelerated filer.
Added 59 new Cell Programs in 2022 (90% growth); downstream milestone potential added over $2.0B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ginkgo Bioworks Holdings, Inc. reported fourth quarter 2022 and year ended December 31, 2022 results: revenue $478 million. Guidance reaffirmed.

Period: fourth quarter 2022 and year ended December 31, 2022
Revenue: $478 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results $478 million of total revenue in 2022

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Ginkgo Bioworks Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-005511

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.